Study Details
Design, interventions, and primary outcomes
About This Study
A prospective, multicenter, observational cohort study to evaluate the efficacy and safety of a novel anti-tumor drug as a radiosensitizer in patients with advanced breast cancer brain metastasis.
Design
Interventions / Regimen
- Drug: Radiotherapy + Novel Anti-tumor Drug — 1. Novel anti-tumor drugs \[including: ADC drugs (such as T-DXd, T-DM1, etc.), CDK4/6 inhibitors, TKI drugs (such as Pyrotinib, Tucatinib, etc.), novel chemotherapy drugs (such as Utidelone, Irinotecan liposomes, etc.), Bevacizumab, PD-1/PD-L1 inhibitors, etc.\] 2. Radiotherapy
Primary Outcomes
- Intracranial Progression-Free Survival (24 months)
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-03-01
Completion: 2028-09-10
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
- Drug: Radiotherapy + Novel Anti-tumor Drug — 1. Novel anti-tumor drugs \[including: ADC drugs (such as T-DXd, T-DM1, etc.), CDK4/6 inhibitors, TKI drugs (such as Pyrotinib, Tucatinib, etc.), novel chemotherapy drugs (such as Utidelone, Irinotecan liposomes, etc.), Bevacizumab, PD-1/PD-L1 inhibitors, etc.\] 2. Radiotherapy